Tardive dyskinesia (TD) is a movement disorder typically caused by taking neuroleptic drugs. Treatment focuses on preventing the recurrence or persistence of symptoms. Tardive dyskinesia (TD) most ...

Currently there are two FDA approved treatment options for tardive dyskinesia. There are two medications that are VMAT2 inhibitors. These are valbenazine (Ingrezza) and deutetrabenazine (Austedo) made ...

Tardive dyskinesia (TD) is a movement disorder. It’s a side effect of taking neuroleptic drugs. Treatment is focused on stopping the recurrence or persistence of symptoms. Tardive dyskinesia (TD) is a ...

Study reveals over half of long-term care residents with tardive dyskinesia do not receive standard treatment, highlighting care gaps. Less than half of patients diagnosed with tardive dyskinesia in ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.

TD often decreases patients’ quality of life through its effects on their physical, emotional, cognitive, and psychosocial well-being. An easy-to-use tool to assess the impact of TD might allow ...

Danielle Nicole Larson, MD, discusses the mental health burden on patients with tardive dyskinesia, and considerations for clinicians who manage this condition.

LONDON--(BUSINESS WIRE)--The global tardive dyskinesia treatment market 2019-2023 is expected to post a CAGR of more than 4% during the forecast period, according to the latest market research report ...

DUBLIN--(BUSINESS WIRE)--The "Global Tardive Dyskinesia Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The Global Tardive Dyskinesia Treatment Market is ...